Celgene, GlobeImmune deal

GlobeImmune extended the option period for Celgene to license pancreatic cancer product GI-4000, according to GlobeImmune's updated S-1 registration statement filed on Aug. 16. Celgene will now have until after GlobeImmune delivers data from the Phase II portion of a planned Phase...